Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Giuseppe Visani, Claudio Giardini, Federica Loscocco, Barbara Guiducci, Cristina Clissa, MD PhD, Elisa Gabucci, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 5463.

https://doi.org/10.1182/blood.V130.Suppl_1.5463.5463

Published: 2017

Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Blood (2013) 122 (21): 2134.

https://doi.org/10.1182/blood.V122.21.2134.2134

Published: 2013

Journal Articles

OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS

Franco Locatelli, MD, Roberto Littera, MD, Daria Pagliara, MD, Benedetta Contoli, PhD, Giovanna Giorgiani, MD, Maria Ester Bernardo, MD, Angela Mastronuzzi, MD, Eugenia Piras, MD, Maria Grazia Orofino, MD, Claudio Giardini, MD, Carlo Carcassi, MD, Giorgio La Nasa, MD

Blood (2011) 118 (21): 149.

https://doi.org/10.1182/blood.V118.21.149.149

Published: 2011

Journal Articles

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Blood (2011) 118 (12): 3419–3425.

https://doi.org/10.1182/blood-2011-04-351924

Published: 2011

Journal Articles

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, MD, Filippo Gherlinzoni, MD, Claudio Giardini, Sadia Falcioni, Federica Loscocco, Francesca Cuberli, Marco Gobbi, MD, Armando Santoro, Barbara Sarina, Marco Rocchi, Alessandro Isidori, MD, PhD

Blood (2010) 116 (21): 31.

https://doi.org/10.1182/blood.V116.21.31.31

Published: 2010

Journal Articles

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Giuseppe Visani, MD, Lara Malerba, MD, Piero Galieni, MD, Claudio Giardini, MD, Sadia Falcioni, MD, Marco Rocchi, Alessandro Isidori, MD, PhD

Blood (2009) 114 (22): 4351.

https://doi.org/10.1182/blood.V114.22.4351.4351

Published: 2009

Journal Articles

Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction

Katharina Fleischhauer, Franco Locatelli, Marco Zecca, Maria Grazia Orofino, Claudio Giardini, Piero De Stefano, Andrea Pession, Angela Maria Iannone, Carlo Carcassi, Elisabetta Zino, Giorgio La Nasa

Blood (2006) 107 (7): 2984–2992.

https://doi.org/10.1182/blood-2005-08-3374

Published: 2006

Journal Articles

Unrelated Donor Bone Marrow Transplantation for Class I-II Thalassemia Pediatric Patients.

Franco Locatelli, MD, Claudio Giardini, MD, Sebastian Giebel, MD, Franca Argiolu, MD, Andrea Pession, MD, Franca Fagioli, MD, Giovanna Giorgiani, MD, Giorgio La Nasa, MD

Blood (2005) 106 (11): 562.

https://doi.org/10.1182/blood.V106.11.562.562

Published: 2005

Journal Articles

Purified T Depleted Peripheral Blood and Bone Marrow CD34 Transplantation from Haploidentical Mother to Child with Thalassemia.

Pietro Sodani, MD, Marco Andreani, PhD, Paola Polchi, MD, Javid Gaziev, MD, Filippo Centis, PhD, Claudio Giardini, MD, Sonia Nesci, PhD, Silvia Cicconi, MD, Luca Spitaleri, MD, Flaminia Cassiani, MD, Guido Lucarelli, MD

Blood (2004) 104 (11): 5161.

https://doi.org/10.1182/blood.V104.11.5161.5161

Published: 2004

Journal Articles

New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years

Pietro Sodani, David Gaziev, Paola Polchi, Buket Erer, Claudio Giardini, Emanuele Angelucci, Donatella Baronciani, Marco Andreani, Marisa Manna, Sonia Nesci, Barbarella Lucarelli, Reginald A. Clift, Guido Lucarelli

Blood (2004) 104 (4): 1201–1203.

https://doi.org/10.1182/blood-2003-08-2800

Published: 2004

Journal Articles

Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes

Giorgio La Nasa, Claudio Giardini, Francesca Argiolu, Franco Locatelli, Marcella Arras, Piero De Stefano, Antonio Ledda, Antonella Pizzati, Maria A. Sanna, Adriana Vacca, Guido Lucarelli, Licinio Contu

Blood (2002) 99 (12): 4350–4356.

https://doi.org/10.1182/blood.V99.12.4350

Published: 2002

Journal Articles

Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation

Emanuele Angelucci, Pietro Muretto, Guido Lucarelli, Marta Ripalti, Donatella Baronciani, Buket Erer, Maria Galimberti, Claudio Giardini, Djavid Gaziev, Paola Polchi, the Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients

Blood (1997) 90 (3): 994–998.

https://doi.org/10.1182/blood.V90.3.994

Published: 1997

NARROW

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction

Unrelated Donor Bone Marrow Transplantation for Class I-II Thalassemia Pediatric Patients.

Purified T Depleted Peripheral Blood and Bone Marrow CD34 Transplantation from Haploidentical Mother to Child with Thalassemia.

New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years

Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes

Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only